#United States #New York #Class Action #Securities Fraud #Ultragenyx

Investors Alert: Upcoming Deadline in Ultragenyx Class Action Lawsuit

Levi & Korsinsky, LLP, an established law firm known for its dedication to protecting shareholder rights, has significant news for investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Those with investments in the company need to be aware that they have until April 6, 2026, to apply as lead plaintiffs in a burgeoning class action lawsuit. This case pertains to investor claims regarding alleged securities fraud that surfaced during the period from August 3, 2023, to December 26, 2025.

Overview of the Lawsuit

The class action aims to advocate for investors who have suffered financial losses due to purportedly misleading statements made by the company’s leadership. The complaint outlines that Ultragenyx’s executives issued overly optimistic remarks about their clinical study of setrusumab, a drug intended to enhance bone density. However, these positive projections were allegedly contradicted by underlying facts, including the failure to demonstrate a decrease in fracture rates, which has raised considerable concerns among shareholders.

On December 29, 2025, Ultragenyx disclosed that its critical Phase III Orbit and Cosmic studies failed to meet their primary endpoints of significantly reducing annual fracture rates when compared to both a placebo and existing treatments. This disappointing announcement triggered a dramatic drop in the company’s stock price, plummeting nearly 42.32% from $34.19 to $19.72 in just one day.

Who Should Act?

If you held shares in Ultragenyx during the relevant timeframe and have incurred losses, now is the time to consider your options. You can submit a request for the Court to appoint you as a lead plaintiff by the April 6 deadline. It’s important to note that you do not need to be a lead plaintiff in order to participate in any potential recovery.

What Does Participation Entail?

Joining the class action does not require any upfront costs or fees from the investors. If you are considered a class member, you may qualify for compensation without having to bear personal expenses. The firm emphasizes that there is no obligation involved in participating in this legal pursuit.

Why Levi & Korsinsky?

Levi & Korsinsky has built an impressive reputation over two decades, successfully recovering hundreds of millions of dollars for aggrieved shareholders. The firm excels in navigating complex securities litigation, employing a team of over 70 professionals who are committed to serving the best interests of investors.

For the last seven consecutive years, the firm has been recognized in ISS Securities Class Action Services’ Top 50 Report, highlighting its standing as one of the leading securities litigation firms in the U.S. Their extensive expertise and commitment to justice make them a reliable choice for anyone considering joining this class action.

How to Contact

Investors wishing to learn more can reach out to Joseph E. Levi, Esq. via email at [email protected] or by phone at (212) 363-7500. For additional details and to understand how to file a claim, please visit their dedicated page at zlk.com.

With the deadline fast approaching, shareholders of Ultragenyx must stay informed and proactive in protecting their investments.